Results 1 to 10 of about 1,087 (181)
Neurology and TherapyCenobamate has demonstrated efficacy in patients with treatment-resistant epilepsy, including patients who continued to have seizures after epilepsy surgery.
Gregory L Krauss +2 more
exaly +3 more sources
Spanish Consensus on the Management of Concomitant Antiseizure Medications When Using Cenobamate in Adults With Drug-Resistant Focal Seizures [PDF]
Epilepsia OpenObjective Cenobamate is an antiseizure medication (ASM) associated with high rates of seizure freedom and acceptable tolerability in patients with focal seizures.
Mar Carreño +2 more
exaly +3 more sources
Safety Assessment of Cenobamate: Real-World Adverse Event Analysis From the FAERS Database
Frontiers in PharmacologyObjective:This study aims to analyze adverse drug events (ADEs) associated with cenobamate from the FAERS database, covering the third quarter of 2020 to the second quarter of 2023.Methods:Data related to cenobamate-associated ADEs from the third quarter
Hui-Qin Xu, Shihao Chen
exaly +4 more sources
Cenobamate: An Appraisal Five Years On [PDF]
Neurology and TherapyCenobamate is an antiseizure medication approved in 2021 as add-on therapy for adults with uncontrolled focal seizures. Early trials showed unusually high seizure freedom rates and a favourable tolerability profile, suggesting that cenobamate may ...
Eugen Trinka +2 more
doaj +4 more sources
Epilepsia OpenObjective In Europe, cenobamate has been approved for use as an adjunctive therapy in adult patients with epilepsy (PWE) with focal‐onset seizures (FOS) who have not responded satisfactorily to treatment with at least two antiseizure medications (ASMs ...
Bernhard J. Steinhoff +1 more
exaly +3 more sources
Increase of Brivaracetam serum concentration with introduction of Cenobamate [PDF]
Frontiers in PharmacologyIntroductionCenobamate is a new antiseizure medication approved for polytherapy of focal epilepsy with complex hepatic metabolism and effects on liver enzymes.
Lena Bender +2 more
doaj +4 more sources
Heliyon, 2023 Background: Cenobamate is an antiseizure medication used to treat partial-onset (focal) seizures. It is a molecule with one chiral center and a unique dual mechanism of action: enhancement of fast and slow inactivation of sodium channels with ...
Susan M. Melnick +2 more
doaj +2 more sources
CPT: Pharmacometrics & Systems PharmacologyCenobamate causes dose‐dependent cytochrome P450 (CYP)2B6 and CYP3A4 induction and CYP2C19 inhibition, raising concern over multi‐pathway drug–drug interactions (DDIs) in patients with epilepsy treated with cardiovascular co‐medications.
Hiroyuki Ichida +7 more
doaj +2 more sources
Epilepsy & Behavior Reports, 2022 Effectiveness and tolerability of adjunctive cenobamate for uncontrolled focal seizures in adults living with a developmental disability are not defined.
Gregory S. Connor, Amanda Williamson
doaj +1 more source
Clinical and Translational Science, 2022 This study was designed to evaluate the effects of cenobamate, an antiseizure medication for focal seizures, on the pharmacokinetics of cytochrome P450 probes (bupropion, CYP2B6; midazolam, CYP3A4/5; warfarin, CYP2C9; and omeprazole, CYP2C19) in healthy ...
Stephen A. Greene +6 more
doaj +1 more source